XOMA Royalty Corp (XOMA) Stock Analysis and Metrics

XOMA Royalty

NASDAQ: XOMA

$40.17 ▲ +0.00 (+0.00%)

At close: Jul 21, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap478.42 Mn

P/E191.88

P/S13.63

Div. Yield0.01

ROIC (Qtr)0.00

Total Debt (Qtr)102.84 Mn

Revenue Growth (1y) (Qtr)207.95

Add ratio to table…

About

XOMA Royalty Corp is a royalty aggregator that provides capital to biotechnology companies in exchange for economic rights to future milestone and royalty payments associated with clinical candidates and approved products. The company operates in the biotechnology and pharmaceutical industries, focusing on acquiring non-dilutive, non-recourse funding opportunities from drug developers and marketers. XOMA Royalty Corp maintains a diversified portfolio of economic rights to future potential milestone and royalty payments associated with over 120 commercial products and pre-commercial therapeutic candidates. The company seeks to generate stockholder value by mitigating single-asset binary risk through portfolio diversification and operating under a capital-efficient and low corporate cost structure.

XOMA Royalty Corp generates revenue primarily through commercial payments, milestone payments, and other fees received from its portfolio of royalty and economic interests. The company receives cash when licensees or partners achieve specified development milestones or when approved products generate net sales that trigger royalty obligations. In 2025, XOMA Royalty Corp received $33.6 million in commercial payments and $16.9 million from milestone payments and other fees, resulting in total cash receipts of $50.5 million from its portfolio. Revenue is derived from a range of therapeutic areas including retinal diseases, pediatric oncology, rare diseases, bleeding disorders, acute pain treatment, and women’s health, among others. The company does not engage in drug development or commercialization itself; instead, it relies on its partners and licensees to bear all research, development, and commercialization costs.

The company does not report distinct operational segments and operates as a single business unit focused on royalty aggregation and acquisition of economic interests in biopharmaceutical assets.

XOMA Royalty Corp occupies a distinctive position in the biotechnology financing landscape as a specialized royalty aggregator, competing with other investment vehicles and funds that seek to acquire royalty streams or provide alternative financing to development-stage companies. Its competitive advantage lies in its focus on early to mid-stage clinical assets with significant commercial potential, its ability to structure complex acquisitions, and its capital-efficient model where partners bear all R&D and commercialization costs. The company differentiates itself by targeting assets with long market exclusivity and therapeutic advantages, and by leveraging its experience in structuring transactions involving publicly traded and private biotech companies. While other large pharmaceutical companies may possess greater financial and technical resources, XOMA Royalty Corp’s low-cost structure and disciplined portfolio approach allow it to participate in high-potential opportunities without assuming development risk.

XOMA Royalty Corp’s customer base consists primarily of biotechnology and pharmaceutical companies that license or partner with the company to secure funding for their drug development programs. These partners include major pharmaceutical firms such as Roche, Johnson & Johnson, Takeda, and Pfizer, as well as specialized biotech companies like Day One Biopharmaceuticals, Zevra Therapeutics, Castle Creek Biosciences, and LAVA Therapeutics. The company also engages with entities such as Rezolute, Pulmokine, Twist Bioscience, and Kuros Biosciences, among others. Through these relationships, XOMA Royalty Corp earns royalties and milestone payments tied to the commercial and developmental performance of products across therapeutic areas including oncology, rare diseases, cardiopulmonary disorders, and women’s health.

Investment Thesis

▲ Bull case

XOMA Royalty is approaching an inflection point where royalty receipts from currently approved products alone will cover core operating costs, creating a self-sustaining engine for future growth without additional capital deployment. This transition, driven by the ramp of OJEMDA and MIPLYFFA alongside steady VABYSMO receipts, reduces reliance on milestone volatility and positions the company to generate increasing free cash flow per share as it continues to repurchase stock. The management’s deliberate focus on shrinking the equity base while maintaining portfolio investments directly amplifies per-share cash flow, a lever that is underappreciated by the market given the company’s current valuation. With unrestricted cash exceeding $83 million and a disciplined approach to capital allocation, XOMA has the financial flexibility to pursue accretive deals or further buybacks without dilution, enhancing long-term shareholder value through compounding returns on a shrinking share count.
The company’s innovative deal structuring—particularly the use of contingent value rights (CVRs) and negative enterprise value acquisitions—allows it to acquire economic interests in development-stage assets with minimal upfront cash while preserving upside potential. In 2025, XOMA added 22 portfolio assets for only $25 million upfront, including late-stage programs like osavampator and volixibat, and expanded its platform technology holdings through the Generation Bio acquisition, which includes ctLNP with liver-bypassing, redosable LNP delivery properties. These transactions not only diversify the portfolio across modalities and indications but also create optionality for future out-licensing revenues without internal R&D spending, a unique advantage over traditional biotech or pure-play royalty companies. The ability to monetize platform technologies via third-party funded development while retaining royalties and milestones through CVRs represents a hidden catalyst that management did not emphasize but could meaningfully extend the portfolio’s growth trajectory beyond traditional drug royalties.
The TREMFYA litigation against Janssen presents a significant asymmetric opportunity with substantial upside and limited downside, yet remains underdiscussed in investor conversations. XOMA’s legal team and external advisers express high confidence in the breach of contract claim based on the original MorphoSys agreement covering phage display and BCE technologies used to create TREMFYA, which has generated approximately $19.7 billion in cumulative net sales since 2017. If successful, the claim could yield low single-digit royalties on this blockbuster asset—potentially translating to hundreds of millions in annual receipts—far exceeding current portfolio scale. Management’s willingness to continue funding the litigation despite uncertainty signals strong internal conviction, and the lack of meaningful reflection of this potential in the stock price suggests the market is overlooking a material, high-conviction catalyst that could redefine the company’s cash flow profile.
XOMA’s portfolio depth provides resilience against clinical setbacks, with over 120 assets, seven commercially generating revenue, and 14 in registrational stage, reducing binary risk compared to traditional drug developers. The recent negative Phase III results for Rezolute’s congenital hyperinsulinism program and Gossamer Bio’s seralutinib were acknowledged without alarm, underscoring confidence in portfolio diversification. Crucially, Rezolute’s ersodetug tumor hyperinsulinism program—potentially the larger opportunity per management’s hint—along with upcoming catalysts like volixibat VISTAS (Q2 2026) and REC-4881 FDA engagement (H1 2026), creates a dense near-term milestone pipeline. These events, combined with the Takeda revenue share deal offering up to $853 million in milestones across nine assets, imply multiple inflection points for royalty acceleration that are not fully priced in, especially given the company’s low base of operations and growing cash flow per share from buybacks.

XOMA Royalty is approaching an inflection point where royalty receipts from currently approved products alone will cover core operating costs, creating a self-sustaining engine for future growth without additional capital deployment. This transition, driven by the ramp of OJEMDA and MIPLYFFA alongside steady VABYSMO receipts, reduces reliance on milestone volatility and positions the company to generate increasing free cash flow per share as it continues to repurchase stock. The management’s deliberate focus on shrinking the equity base while maintaining portfolio investments directly amplifies per-share cash flow, a lever that is underappreciated by the market given the company’s current valuation. With unrestricted cash exceeding $83 million and a disciplined approach to capital allocation, XOMA has the financial flexibility to pursue accretive deals or further buybacks without dilution, enhancing long-term shareholder value through compounding returns on a shrinking share count.
The company’s innovative deal structuring—particularly the use of contingent value rights (CVRs) and negative enterprise value acquisitions—allows it to acquire economic interests in development-stage assets with minimal upfront cash while preserving upside potential. In 2025, XOMA added 22 portfolio assets for only $25 million upfront, including late-stage programs like osavampator and volixibat, and expanded its platform technology holdings through the Generation Bio acquisition, which includes ctLNP with liver-bypassing, redosable LNP delivery properties. These transactions not only diversify the portfolio across modalities and indications but also create optionality for future out-licensing revenues without internal R&D spending, a unique advantage over traditional biotech or pure-play royalty companies. The ability to monetize platform technologies via third-party funded development while retaining royalties and milestones through CVRs represents a hidden catalyst that management did not emphasize but could meaningfully extend the portfolio’s growth trajectory beyond traditional drug royalties.
The TREMFYA litigation against Janssen presents a significant asymmetric opportunity with substantial upside and limited downside, yet remains underdiscussed in investor conversations. XOMA’s legal team and external advisers express high confidence in the breach of contract claim based on the original MorphoSys agreement covering phage display and BCE technologies used to create TREMFYA, which has generated approximately $19.7 billion in cumulative net sales since 2017. If successful, the claim could yield low single-digit royalties on this blockbuster asset—potentially translating to hundreds of millions in annual receipts—far exceeding current portfolio scale. Management’s willingness to continue funding the litigation despite uncertainty signals strong internal conviction, and the lack of meaningful reflection of this potential in the stock price suggests the market is overlooking a material, high-conviction catalyst that could redefine the company’s cash flow profile.
XOMA’s portfolio depth provides resilience against clinical setbacks, with over 120 assets, seven commercially generating revenue, and 14 in registrational stage, reducing binary risk compared to traditional drug developers. The recent negative Phase III results for Rezolute’s congenital hyperinsulinism program and Gossamer Bio’s seralutinib were acknowledged without alarm, underscoring confidence in portfolio diversification. Crucially, Rezolute’s ersodetug tumor hyperinsulinism program—potentially the larger opportunity per management’s hint—along with upcoming catalysts like volixibat VISTAS (Q2 2026) and REC-4881 FDA engagement (H1 2026), creates a dense near-term milestone pipeline. These events, combined with the Takeda revenue share deal offering up to $853 million in milestones across nine assets, imply multiple inflection points for royalty acceleration that are not fully priced in, especially given the company’s low base of operations and growing cash flow per share from buybacks.

▼ Bear case

XOMA Royalty’s growth narrative is heavily dependent on the continued commercial success of a small number of key assets—VABYSMO, OJEMDA, and MIPLYFFA—which together drive the majority of royalty receipts, creating concentration risk that the company downplays despite its broad portfolio count. While management highlights over 120 assets, only seven are commercially available and generating meaningful cash flow, with the rest reliant on unpredictable clinical, regulatory, or licensing outcomes. The optimism surrounding OJEMDA’s EU CHMP opinion and Japan milestone ignores the reality that conditional approvals often come with restrictions, and Ipsen’s commercialization track record outside the U.S. remains unproven at scale. Similarly, MIPLYFFA’s launch by Zevra Therapeutics, while approved, faces uncertain uptake in the ultra-rare Niemann-Pick disease type C market, where pricing and reimbursement challenges could limit peak sales well below optimistic assumptions, making the royalty stream more fragile than portrayed.
The Blue Owl loan, while nonrecourse and secured only by VABYSMO receipts, represents a structural overhang that could constrain financial flexibility if VABYSMO growth decelerates, despite management’s confidence in repayment by 2030. Any slowdown in the ophthalmology market—particularly in the U.S., where Roche has noted reacceleration but has not yet delivered sustained growth—could extend the loan’s lifespan, delaying the return of VABYSMO economics to XOMA and tying up cash flow that could otherwise be used for buybacks or new deals. Furthermore, the company’s reliance on opportunistic share repurchases to boost per-share metrics assumes sustained excess cash flow, which may not hold if royalty growth plateaus or litigation costs rise unexpectedly, undermining the core bullish thesis of accelerating per-share returns through equity base reduction.
The TREMFYA litigation, while framed as high-confidence by management, carries substantial binary risk and uncertain damages, with no guarantee of success or meaningful recovery even if liability is established. The claim hinges on interpreting a decades-old agreement regarding technology transfer that never specified commercial royalty rates, making any potential payout speculative and subject to judicial discretion. Given that Janssen is a deep-pocketed defendant with strong legal resources and the parent company J&J has successfully defended similar IP disputes in the past, the likelihood of a material settlement or award is far from assured. Management’s willingness to fund the suit does not equate to probability of success, and allocating capital to litigation instead of portfolio growth or buybacks represents an opportunity cost that could drag on returns if the case prolongs or fails.
XOMA’s strategy of acquiring negative enterprise value companies and platform technologies through sweat equity deals, while innovative, carries execution and integration risks that are not adequately addressed, particularly regarding the Generation Bio ctLNP and iqDNA platforms. The company explicitly states it will not invest R&D dollars into these technologies, relying entirely on third parties to fund development and assume technical risk—a significant limitation that reduces the likelihood of successful out-licensing. Without internal development capability, XOMA’s ability to credibly license ctLNP outside Moderna’s field of use is constrained by existing partnerships and potential IP entanglements, while the iqDNA platform remains early-stage with no clear path to monetization. These platform bets resemble speculative options rather than core portfolio holdings, and the optimism around generating “mid- to long-term” royalties from them lacks near-term visibility, making them more aspirational than actionable in the current investment thesis.

XOMA Royalty’s growth narrative is heavily dependent on the continued commercial success of a small number of key assets—VABYSMO, OJEMDA, and MIPLYFFA—which together drive the majority of royalty receipts, creating concentration risk that the company downplays despite its broad portfolio count. While management highlights over 120 assets, only seven are commercially available and generating meaningful cash flow, with the rest reliant on unpredictable clinical, regulatory, or licensing outcomes. The optimism surrounding OJEMDA’s EU CHMP opinion and Japan milestone ignores the reality that conditional approvals often come with restrictions, and Ipsen’s commercialization track record outside the U.S. remains unproven at scale. Similarly, MIPLYFFA’s launch by Zevra Therapeutics, while approved, faces uncertain uptake in the ultra-rare Niemann-Pick disease type C market, where pricing and reimbursement challenges could limit peak sales well below optimistic assumptions, making the royalty stream more fragile than portrayed.
The Blue Owl loan, while nonrecourse and secured only by VABYSMO receipts, represents a structural overhang that could constrain financial flexibility if VABYSMO growth decelerates, despite management’s confidence in repayment by 2030. Any slowdown in the ophthalmology market—particularly in the U.S., where Roche has noted reacceleration but has not yet delivered sustained growth—could extend the loan’s lifespan, delaying the return of VABYSMO economics to XOMA and tying up cash flow that could otherwise be used for buybacks or new deals. Furthermore, the company’s reliance on opportunistic share repurchases to boost per-share metrics assumes sustained excess cash flow, which may not hold if royalty growth plateaus or litigation costs rise unexpectedly, undermining the core bullish thesis of accelerating per-share returns through equity base reduction.
The TREMFYA litigation, while framed as high-confidence by management, carries substantial binary risk and uncertain damages, with no guarantee of success or meaningful recovery even if liability is established. The claim hinges on interpreting a decades-old agreement regarding technology transfer that never specified commercial royalty rates, making any potential payout speculative and subject to judicial discretion. Given that Janssen is a deep-pocketed defendant with strong legal resources and the parent company J&J has successfully defended similar IP disputes in the past, the likelihood of a material settlement or award is far from assured. Management’s willingness to fund the suit does not equate to probability of success, and allocating capital to litigation instead of portfolio growth or buybacks represents an opportunity cost that could drag on returns if the case prolongs or fails.
XOMA’s strategy of acquiring negative enterprise value companies and platform technologies through sweat equity deals, while innovative, carries execution and integration risks that are not adequately addressed, particularly regarding the Generation Bio ctLNP and iqDNA platforms. The company explicitly states it will not invest R&D dollars into these technologies, relying entirely on third parties to fund development and assume technical risk—a significant limitation that reduces the likelihood of successful out-licensing. Without internal development capability, XOMA’s ability to credibly license ctLNP outside Moderna’s field of use is constrained by existing partnerships and potential IP entanglements, while the iqDNA platform remains early-stage with no clear path to monetization. These platform bets resemble speculative options rather than core portfolio holdings, and the optimism around generating “mid- to long-term” royalties from them lacks near-term visibility, making them more aspirational than actionable in the current investment thesis.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password